Sunday, October 19, 2025

Latest

Cresco Labs: Canaccord Bumps Price Target Up To $20.50

Wednesday, Canaccord came out with their updated valuations for the large three multi-state operators. With respect to Cresco Labs (CSE: CL), they raised their 12-month price target to C$20.50 from C$16 while reiterating their Speculative Buy rating on the company.

Cresco Labs currently has 15 analysts covering the company with a weighted 12-month price target of C$16.86. This is up from the average at the start of the month, which was C$16.49. Three analysts have strong buys, 11 analysts have buy ratings, and one analyst has a hold rating.

Derek Dley, Canaccord’s U.S cannabis analyst, said the primary reason for the price target increase is due to “the recent Democratic Senate win in Georgia and what we believe will be an acceleration of pro-cannabis legislation over the medium term.” He writes, “We believe Cresco’s focus on winning share in the wholesale channel while also capitalizing on its key retail assets will realize high returns on its invested capital over the long term.”

Dley touches on the overall sentiment towards the U.S cannabis sector. He says that after the Georgia run-offs, investor sentiment has improved greatly and to, “expect an increasing likelihood of key pro-cannabis-related legislation over the medium term, providing strong secular tailwinds for the industry.”

Alongside the broad sentiment improving, Dley says, “Sentiment towards cannabis in Cresco’s core states of operation, namely Illinois and Pennsylvania (where the company also completed two meaningful production/ cultivation facility expansions), also continues to improve.” He forecasts that Illinois will surpass U$1 billion in 2020, mainly due to the state being supply-constrained, causing price dislocations.

Onto another supply-constrained market, Pennsylvania, Dley says that Governor Tom Wolf has recently taken a more positive tone, suggesting the legalization of adult-use cannabis could be on the horizon. He writes, “we estimate [this] could expand the current market size as much as 2-3x.”

Dley says that Cresco Labs’ third-quarter results were an inflection point for the company due to increased capacity during the first half of 2021. Cresco Labs boasted a 63% increase in revenue while maintaining flat SG&A. This in turn caused EBITDA to grow 182%.

Dley ends the note by writing, “In our view, Cresco is well-positioned to capitalize on the increasing acceptance of cannabis within its core states, boasts a well-regarded management team, and offers investors a differentiated cannabis opportunity through its focus on both wholesale and retail in highly strategic geographic markets.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

Netflix: Canaccord Increases Subscriber Growth Estimates

Last week, Netflix (NASDAQ: NFLX) announced that Universal and Netflix have extended their exclusive license...

Friday, July 23, 2021, 04:43:00 PM

GameStop: Consensus Estimates Point To Negative EBITDA For Q3

GameStop (NYSE: GME) will be reporting its third quarter financial results on December 8th after...

Wednesday, December 8, 2021, 10:12:00 AM

GAGE Cannabis: PI Financial Reiterates Their Street High Target, Lowers 2021 Estimates

On August 24, Gage Growth Corp. (CSE: GAGE) announced their second quarter financial results. The...

Saturday, August 28, 2021, 11:13:00 AM

Organigram: Haywood Raises Estimates Betting On Increased Market Share

On January 11th, Organigram Holdings (TSX: OGI) issued its second fiscal quarter earnings for 2022....

Saturday, January 15, 2022, 11:09:00 AM

BMO Reiterates Targets On Couche-Tard Despite Q2 Earnings Beat

On August 30, Alimentation Couche-Tard Inc. (TSX: ATD.B) announced its fiscal first quarter financial results...

Friday, September 2, 2022, 03:02:00 PM